|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: IL34 |
Gene summary for IL34 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | IL34 | Gene ID | 146433 |
| Gene name | interleukin 34 | |
| Gene Alias | C16orf77 | |
| Cytomap | 16q22.1 | |
| Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | Q6ZMJ4 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 146433 | IL34 | C43 | Human | Oral cavity | OSCC | 8.10e-15 | 3.24e-01 | 0.1704 |
| 146433 | IL34 | C46 | Human | Oral cavity | OSCC | 2.03e-19 | 4.79e-01 | 0.1673 |
| 146433 | IL34 | LN38 | Human | Oral cavity | OSCC | 2.29e-02 | 7.04e-01 | 0.168 |
| 146433 | IL34 | LN46 | Human | Oral cavity | OSCC | 1.93e-11 | 5.39e-01 | 0.1666 |
| 146433 | IL34 | NEOLP-1 | Human | Oral cavity | NEOLP | 4.23e-05 | 3.33e-01 | -0.0194 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:003009920 | Oral cavity | OSCC | myeloid cell differentiation | 213/7305 | 381/18723 | 1.24e-11 | 4.42e-10 | 213 |
| GO:007190010 | Oral cavity | OSCC | regulation of protein serine/threonine kinase activity | 201/7305 | 359/18723 | 3.90e-11 | 1.27e-09 | 201 |
| GO:000257310 | Oral cavity | OSCC | myeloid leukocyte differentiation | 119/7305 | 208/18723 | 7.29e-08 | 1.29e-06 | 119 |
| GO:00107209 | Oral cavity | OSCC | positive regulation of cell development | 159/7305 | 298/18723 | 3.06e-07 | 4.66e-06 | 159 |
| GO:00434054 | Oral cavity | OSCC | regulation of MAP kinase activity | 101/7305 | 177/18723 | 8.13e-07 | 1.12e-05 | 101 |
| GO:004586016 | Oral cavity | OSCC | positive regulation of protein kinase activity | 194/7305 | 386/18723 | 3.90e-06 | 4.59e-05 | 194 |
| GO:000268714 | Oral cavity | OSCC | positive regulation of leukocyte migration | 78/7305 | 135/18723 | 7.43e-06 | 8.08e-05 | 78 |
| GO:003367418 | Oral cavity | OSCC | positive regulation of kinase activity | 228/7305 | 467/18723 | 8.31e-06 | 8.90e-05 | 228 |
| GO:19031316 | Oral cavity | OSCC | mononuclear cell differentiation | 210/7305 | 426/18723 | 8.44e-06 | 9.02e-05 | 210 |
| GO:00507696 | Oral cavity | OSCC | positive regulation of neurogenesis | 120/7305 | 225/18723 | 8.45e-06 | 9.02e-05 | 120 |
| GO:00420635 | Oral cavity | OSCC | gliogenesis | 154/7305 | 301/18723 | 1.10e-05 | 1.14e-04 | 154 |
| GO:00719028 | Oral cavity | OSCC | positive regulation of protein serine/threonine kinase activity | 107/7305 | 200/18723 | 2.12e-05 | 2.02e-04 | 107 |
| GO:00507679 | Oral cavity | OSCC | regulation of neurogenesis | 179/7305 | 364/18723 | 4.49e-05 | 3.84e-04 | 179 |
| GO:190370618 | Oral cavity | OSCC | regulation of hemopoiesis | 180/7305 | 367/18723 | 5.16e-05 | 4.30e-04 | 180 |
| GO:0014009 | Oral cavity | OSCC | glial cell proliferation | 34/7305 | 51/18723 | 5.83e-05 | 4.80e-04 | 34 |
| GO:000268510 | Oral cavity | OSCC | regulation of leukocyte migration | 108/7305 | 210/18723 | 1.63e-04 | 1.13e-03 | 108 |
| GO:00321037 | Oral cavity | OSCC | positive regulation of response to external stimulus | 203/7305 | 427/18723 | 1.79e-04 | 1.22e-03 | 203 |
| GO:00192214 | Oral cavity | OSCC | cytokine-mediated signaling pathway | 222/7305 | 472/18723 | 2.02e-04 | 1.35e-03 | 222 |
| GO:00519624 | Oral cavity | OSCC | positive regulation of nervous system development | 135/7305 | 272/18723 | 2.20e-04 | 1.44e-03 | 135 |
| GO:00509216 | Oral cavity | OSCC | positive regulation of chemotaxis | 76/7305 | 141/18723 | 2.30e-04 | 1.49e-03 | 76 |
| Page: 1 2 3 4 5 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| IL34 | CSF1R | IL34_CSF1R | CSF | Cervix | CC |
| IL34 | CSF1R | IL34_CSF1R | CSF | CRC | AD |
| IL34 | CSF1R | IL34_CSF1R | CSF | HNSCC | Healthy |
| IL34 | CSF1R | IL34_CSF1R | CSF | HNSCC | OSCC |
| IL34 | CSF1R | IL34_CSF1R | CSF | HNSCC | Precancer |
| IL34 | CSF1R | IL34_CSF1R | CSF | Liver | HCC |
| IL34 | CSF1R | IL34_CSF1R | CSF | Prostate | ADJ |
| IL34 | CSF1R | IL34_CSF1R | CSF | Prostate | BPH |
| IL34 | CSF1R | IL34_CSF1R | CSF | Skin | ADJ |
| IL34 | CSF1R | IL34_CSF1R | CSF | Skin | AK |
| IL34 | CSF1R | IL34_CSF1R | CSF | THCA | Cancer |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| IL34 | SNV | Missense_Mutation | c.643N>T | p.Pro215Ser | p.P215S | Q6ZMJ4 | protein_coding | tolerated_low_confidence(0.39) | benign(0.005) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| IL34 | SNV | Missense_Mutation | rs368143418 | c.311N>T | p.Ser104Leu | p.S104L | Q6ZMJ4 | protein_coding | tolerated(0.44) | benign(0.003) | TCGA-B6-A0I9-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
| IL34 | SNV | Missense_Mutation | c.39N>G | p.Ile13Met | p.I13M | Q6ZMJ4 | protein_coding | deleterious(0) | benign(0.329) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD | |
| IL34 | SNV | Missense_Mutation | rs142214904 | c.508C>T | p.Arg170Trp | p.R170W | Q6ZMJ4 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-AA-3710-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| IL34 | SNV | Missense_Mutation | rs369011177 | c.25N>T | p.Arg9Cys | p.R9C | Q6ZMJ4 | protein_coding | tolerated(0.17) | possibly_damaging(0.648) | TCGA-CK-4947-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Other, specify in notes | folinic | SD |
| IL34 | SNV | Missense_Mutation | novel | c.305N>A | p.Thr102Asn | p.T102N | Q6ZMJ4 | protein_coding | deleterious(0.02) | possibly_damaging(0.466) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| IL34 | SNV | Missense_Mutation | novel | c.132N>T | p.Lys44Asn | p.K44N | Q6ZMJ4 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| IL34 | SNV | Missense_Mutation | c.11N>A | p.Gly4Asp | p.G4D | Q6ZMJ4 | protein_coding | deleterious(0.01) | possibly_damaging(0.895) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| IL34 | SNV | Missense_Mutation | novel | c.109N>A | p.Val37Ile | p.V37I | Q6ZMJ4 | protein_coding | tolerated(0.9) | benign(0.001) | TCGA-AP-A1DM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| IL34 | SNV | Missense_Mutation | novel | c.698N>C | p.Val233Ala | p.V233A | Q6ZMJ4 | protein_coding | tolerated_low_confidence(0.13) | benign(0.001) | TCGA-D1-A16Y-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |